Soluble transferrin receptor and depth of bone marrow suppression following high dose chemotherapy.
BACKGROUND
Soluble transferrin receptor (sTfR) reflects erythropoietic activity in the bone marrow. We have sought to identify whether serial measurement of sTfR may predict depth or duration of myelosuppression in patients receiving high dose chemotherapy.


METHODS
We prospectively measured serial sTfR in nine consecutive patients with haematologic malignancy admitted for various high dose regimens. The sTfR nadir was associated with white cell nadir, and sTfR nadir and day 5 sTfR were inversely associated with the number of red cell transfusions required.


CONCLUSIONS
Our data suggest that sTfR may be helpful in predicting the degree of bone marrow suppression in patients receiving intensive chemotherapy.
Pasricha
Sant-Rayn
SR
Department of Clinical Haematology and Bone Marrow Transplant, The Alfred Hospital, Commercial Road, Melbourne, 3004, Victoria, Australia.
Rooney
Poyap
P
Schneider
Hans
H
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D017707:Erythrocyte Transfusion; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007970:Leukopenia / Q000209:etiology*; D008297:Male; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011990:Receptors, Transferrin / Q000378:metabolism*; D016879:Salvage Therapy; D033581:Stem Cell Transplantation / Q000009:adverse effects
D000970:Antineoplastic Agents; D011990:Receptors, Transferrin